You are here: Home » News-IANS » Health-Medicine
Business Standard

HIV drug that can adversely affect infant development identified

IANS  |  New York 

An anti-retroviral (ARV) drug sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy may have adverse effects on infant development, new research has found.

The researchers found that one-year-olds whose mothers took the drug atazanavir during pregnancy have slightly reduced scores for language and social-emotional development, compared to ARV regimens not containing atazanavir.

The findings were detailed in the journal AIDS, official journal of the International AIDS Society.

"These results may be useful in treatment planning for women with HIV infection," the study said.

The researchers analysed data on 917 infants who were born to HIV-positive mothers but did not acquire HIV infection.

As recommended by current US and European guidelines, all mothers took ARV therapy during pregnancy to reduce the risk of transmitting HIV.

At around one year old, the infants were assessed on a standard test of infant development.

The results showed language development scores were lower for infants whose mothers received atazanavir.

Scores for social-emotional development were also lower for infants whose mothers took atazanavir.

These differences "may not have large clinical implications, but they add another risk to the constellation of existing biological and socio-environmental risk factors to which these children are often exposed," said one of the researchers Ellen Caniglia from Harvard T.J. Chan School of Public Health in Boston, US.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 23 2016. 15:30 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU